Chiquita Brooks-LaSure, CMS administrator (Chip Somodevilla/Getty Images)
Pharma companies to remain mum on CMS' initial offers next week for the first year of IRA negotiations
One of the biggest (if not the single biggest) gripe that the pharma industry has with the Inflation Reduction Act is that it considers the price negotiation process, which kicks off with an initial offer from CMS to the biopharma companies on Feb. 1, to be nothing more than price setting.
The price-setting mantra has stuck ever since it became clear that the companies cannot afford to say no to whatever price the process ends on, as such a move would trigger steep fines, or even a loss of access to Medicare for all of their products.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
